Pharma Equity Group udvikler nye lægemidler til lokalbehandling af alvorlige og livstruende betændelsessygdomme hvor der i dag ikke findes en tilstrækkelig behandling. Selskabet benytter sig af repositionering af eksisterende lægemidler og fører lægemiddelkandidater frem til et klinisk fase III stadie hvorefter det overgives til en strategisk partner, der vil færdigudvikle produkterne og bringe dem på markedet, enten selvstændigt eller i samarbejde med selskabet.
PEG announced this morning that its subsidiary Reponex Pharmaceuticals has received a notification from the European Patent Office (EPO) of its intention to grant a European patent covering compositions and methods for the treatment of Inflammatory Bowel Disease (IBD).Strategically, the patent grant supports PEG's broader narrative of gradually de-risking its repositioning-based pipeline through a combination of clinical, commercial, and IP-related milestones
In connection with the publication of Pharma Equity Group's annual report for 2025, 2026 guidance and ongoing clinical developments, we have published our investment case.
Our investment case covers the key investment reasons and risks and valuation perspectives.
PEG's investment case centres on de-risking its pipeline through clinical progress and strategic partnerships, while diversifying into revenue-generating assets through its expanded Life Science consolidator strategy. The drug repositioning approach — repurposing previously approved active pharmaceutical ingredients for new therapeutic applications — aims to reduce clinical risk relative to de novo drug development, and the out-licensing model post-Phase II is designed to limit capital requirements and execution risk.
Pharma Equity Group offentliggjorde i dag sit regnskab for 2025 samt løftede for første sløret for 2026 guidance. I den forbindelse havde vi i dag fornøjelsen af CEO Christian H. Tange, der gennemgik resultaterne og highlights for 2025, forventningerne til 2026 samt svarede på spørgsmål fra publikum
Pharma Equity Group ventes at offentliggøre sit årsregnskab for 2025 den 25. marts 2026. Samme dag kl. 14.00 præsenterer direktør Christian H. Tange resultaterne og svarer på spørgsmål fra publikum.
